Hood River Capital Management LLC increased its holdings in BioTelemetry, Inc. (NASDAQ:BEAT) by 13.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 907,939 shares of the medical research company’s stock after buying an additional 109,921 shares during the period. BioTelemetry accounts for 1.9% of Hood River Capital Management LLC’s investment portfolio, making the stock its 11th biggest position. Hood River Capital Management LLC owned approximately 2.81% of BioTelemetry worth $29,962,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Quantbot Technologies LP boosted its holdings in BioTelemetry by 577.1% in the 3rd quarter. Quantbot Technologies LP now owns 9,087 shares of the medical research company’s stock worth $299,000 after buying an additional 7,745 shares during the period. Comerica Bank boosted its holdings in BioTelemetry by 60.2% in the 3rd quarter. Comerica Bank now owns 49,515 shares of the medical research company’s stock worth $1,419,000 after buying an additional 18,600 shares during the period. Bank of New York Mellon Corp boosted its holdings in BioTelemetry by 39.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,435,701 shares of the medical research company’s stock worth $47,379,000 after buying an additional 404,107 shares during the period. Rhumbline Advisers boosted its holdings in BioTelemetry by 5.2% in the 3rd quarter. Rhumbline Advisers now owns 56,903 shares of the medical research company’s stock worth $1,878,000 after buying an additional 2,815 shares during the period. Finally, Advisor Group Inc. boosted its holdings in BioTelemetry by 18.8% in the 3rd quarter. Advisor Group Inc. now owns 23,751 shares of the medical research company’s stock worth $784,000 after buying an additional 3,754 shares during the period. 77.87% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/11/16/hood-river-capital-management-llc-has-29-96-million-position-in-biotelemetry-inc-beat.html.

BioTelemetry, Inc. (NASDAQ BEAT) traded up $0.93 during trading on Thursday, hitting $25.08. 308,821 shares of the stock traded hands, compared to its average volume of 475,694. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.48 and a current ratio of 1.60. The stock has a market cap of $800.48, a PE ratio of 33.84, a P/E/G ratio of 1.54 and a beta of 0.58. BioTelemetry, Inc. has a 12-month low of $18.45 and a 12-month high of $39.20.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings data on Tuesday, November 7th. The medical research company reported $0.16 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by ($0.09). The company had revenue of $81.02 million for the quarter, compared to analysts’ expectations of $82.10 million. BioTelemetry had a net margin of 16.10% and a return on equity of 13.66%. The business’s quarterly revenue was up 52.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.21 EPS. equities research analysts forecast that BioTelemetry, Inc. will post 0.83 EPS for the current year.

Several research analysts have commented on the stock. BidaskClub downgraded shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Sidoti reissued a “buy” rating and issued a $49.00 price target (up from $42.00) on shares of BioTelemetry in a report on Thursday, August 10th. Dougherty & Co reissued a “buy” rating and issued a $40.00 price target on shares of BioTelemetry in a report on Wednesday, November 8th. Zacks Investment Research raised shares of BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $39.00 price target for the company in a report on Friday, August 11th. Finally, Benchmark Co. raised their price target on shares of BioTelemetry from $38.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, July 19th. Two research analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $42.86.

BioTelemetry Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Stock Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related stocks with our FREE daily email newsletter.